Docetaxel 2-weeks Regimen in the Treatment of HER2 Negative Metastatic Breast Cancer
Status:
Unknown status
Trial end date:
2019-12-30
Target enrollment:
Participant gender:
Summary
A Randomized, Controlled Clinical Trial Comparing the Efficacy and Safety of a Single Agent
Docetaxel 2-Weeks Regimen in the Treatment of HER2 Negative Metastatic Breast Cancer to a
3-Weeks Regimen